Evidence check: CYP2C19 in the context of Blutzucker

The evidence for a direct link between CYP2C19 polymorphisms and blood glucose levels is weak and unclear. CYP2C19 is a key drug-metabolizing enzyme (e.g., for clopidogrel, proton pump inhibitors). Some studies have explored associations between certain CYP2C19 variants and type 2 diabetes risk or metformin response, but results are inconsistent and effect sizes are small. Most findings come from exploratory analyses or small cohorts and have not been replicated in large, independent studies. Confounders such as ethnicity, medication use, and lifestyle further limit interpretability. From a nutrigenetic perspective, there is no established recommendation based on CYP2C19. A genetic test for CYP2C19 in the context of blood sugar is therefore best classified as exploratory or marketing-driven. For assessing glucose metabolism, established biomarkers (fasting glucose, HbA1c, insulin) and lifestyle factors are far more relevant. Caution: a genetic test does not replace medical evaluation of abnormal blood glucose levels.